Expression of Tn1/3 Transposase

It has previously been shown that the only sequences near the termini of Tn1/3 essential for the first step of the transposition process of these elements are the two 38bp. perfect inverted repeats at the extreme ends of the elements. This finding has been confirmed and it has also been shown that both of these sequences are equally good substrates for transposition. Also, it was shown that Tn1/3 transposition normally acts to replicate the DNA sequences that correspond to the entire transposon sequences. Further indirect evidence for the binding of Tn1 transposase to the inverted repeat sequences of Tn1/3 was obtained, supporting the hypothesis that it is to and upon these sequences that transposase binds and acts. The location of the HincII site present in Tn1 but absent in Tn3 has , also been determined by DNA sequencing and found to be at a position in Tn1 equivalent to co-ordinates 3037-3042 in Tn3, with cleavage occurring between base pairs 3039 and 3040. Thus, this site lies just within the tnpA gene coding region, near its N-terminal end. The sequence of 114bp. of Tn1 lying to the left of this site (i.e. extending towards the C-terminus of the tnpA gene) was determined and was found to have 97/114 bp. (=85 1%) homology at the DNA level and 37/38 residue (=97.4%) homology at the amino acid level with Tn3. This confirmed the prediction of a high degree of homology between the two elements, which had been made on the basis of their very similar restriction profiles. Using this information, a plamid (pSN015) was constructed that produced a fusion protein consisting of the whole Tn1 transposase protein with its three N-terminal amino acid residues removed and replaced by the first eleven N-terminal amino acid residues of B-galactosidase. As judged by the analysis of plasmid encoded proteins expressed in E. coli K-12 minicells, pSN015 did produce more protein than the derepressed Tn1 derivative Tn103 carried on a plasmid (pMB9) with a copy number c. 1/4 of that of pSN015. Yet the transposition of Tn3651 mediated in trans by each of these plasmids occurred at very similar frequencies at both 3

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Survival of 3T3 cells expressing or co-expressing bFGF and/or IGF-I and/or IGF-II in low serum and serum free media

The aim of this study was to improve the survival ofNIH3T3 cells in low serum or serum-free media by theendogenous expression of recombinant bFGF (basicfibroblast growth factor) and/or IGF (insulin-likegrowth factor) -I and II. Expression was detected byWestern blotting, and the growth characteristics ofdifferent transfected cell lines investigated in bothserum-free and low serum conditions and also in softagar. Morphological changes and the growth rate werecompared with growth in normal serum-containingmedium. The experimental data suggested that theexpression of either bFGF alone, or the co-expressionof bFGF and either IGF-I or II could improve thesurvival of NIH3T3 cells in low serum or serum-freemedia. The use of such lines could decrease the use ofserum in cell culture and thus both reduce the costsinvolved in this technique and simplify thedown-stream purification procedure in protein harvest.Hence, such lines may be of value in both experimentaland industrial applications

Production of transgenic lamb foetuses by sub-zonal injection of feline leukaemia virus

No abstract available

Plasmids containing a murine autonomous replicating sequence in transgenic mice: function as an origin of replication, but inability to persist in an episomal state

No abstract available

Plasmids containing a murine autonomous replicating sequence in transgenic mice:function as an origin of replication but inability to persist in an episomal state

No abstract available